Current Molecularly Targeting Therapies in NSCLC and Melanoma

Author(s): Supriya Rajanna, Ichwaku Rastogi, Luke Wojdyla, Hiroko Furo, Agnes Kulesza, Leo Lin, Bonnie Sheu, Mark rakes, Marko Ivanovich, Neelu Puri

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 15 , Issue 7 , 2015

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Surgery, radiation therapy, and chemotherapy are the traditional options to control tumor progression. However, these strategies are fraught with harmful side effects and are ineffective in metastatic and advanced cancers. Biomarkers that are overexpressed in cancers and are involved in cell growth, proliferation, migration, and survival have recently become the focus of new molecular targeting therapies. Novel therapies targeting biomarkers have roles in tumorigenesis that are overexpressed in cancers may be more efficacious and less toxic in comparison to traditional therapies. These therapies include the use of tyrosine kinase inhibitors and monoclonal antibodies for the treatment of cancer. However, the efficacy of these therapies is limited due to the development of drug resistance after prolonged treatment. Current research is focused on understanding mechanisms of resistance to overcome the barriers limiting the use of these targeting therapies in the treatment of cancer. In this review, we will discuss the clinical status of tyrosine kinase inhibitors and monoclonal antibodies against several prevalent biomarkers that are candidates for therapy in non-small cell lung cancer (NSCLC) and melanoma.

Keywords: Melanoma, monoclonal antibodies, NSCLC, tyrosine kinase inhibitor.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 12 July, 2015
Page: [856 - 868]
Pages: 13
DOI: 10.2174/1871520615666150202100130
Price: $65

Article Metrics

PDF: 41